Early-Stage CLL Treatment with Ibrutinib Delays Progression, No Survival Benefit
The following is a summary of “Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial,” published in the November 2024 issue of Oncology by Lang ...
